MRI-Guided HIFU Effective in Intermediate-Risk Prostate Cancer
MRI-guided high-intensity focused ultrasound (HIFU) is effective in patients with intermediate-risk prostate cancer, researchers reported. According to the team’s multicenter, single-arm, phase IIb study of 101 patients who received the treatment, 96% had no evidence of grade group 2 or higher prostate cancer on 6-month MRI-targeted and systematic biopsy in the treated area of the […]
Xtandi During AS Reduced Progression Risk in Early Prostate Cancer
Patients with low- or intermediate-risk localized prostate cancer who received enzalutamide (Xtandi) monotherapy saw a reduced risk of cancer progression, according to a randomized phase II trial. Among 227 patients on active surveillance (AS), treatment with enzalutamide reduced the risk of pathological or therapeutic prostate cancer progression by 46% compared with AS alone (HR 0.54, […]
Just How Effective Is PSA Screening?
NEW ORLEANS — Prostate cancer screening with prostate-specific antigen (PSA) blood testing appears to have a more favorable benefit-to-harm trade-off than originally estimated, particularly among Black men, according to research presented here. Using the most conservative assumptions about the benefits of screening, investigators found that among men of all races, one death was prevented for […]
Mental Health Issues Common, Often Overlooked in Prostate Cancer
NEW ORLEANS — More than a third of men with newly diagnosed prostate cancer had at least one mental health issue, which had a strong association with prior psychological wellbeing, a prospective cohort study showed. Almost 30% of the men had a fear of cancer recurrence or poor prognosis, and 22% met diagnostic criteria for […]
How tumor cells use mitochondria to keep growing
Hormone therapy is often used to treat prostate cancer that has spread to other parts of the body, but many patients develop resistance to hormone therapy, causing their disease to become more aggressive and potentially more deadly. “One of the big challenges we have in the field is that the majority of prostate cancer therapies […]
End of the Line for a Failed Prostate Cancer Drug
The androgen synthesis inhibitor orteronel failed to improve survival in metastatic hormone-sensitive prostate cancer (mHSPC) despite a twofold improvement in progression-free survival (PFS) versus standard androgen-deprivation therapy (ADT), a large randomized trial showed. Patients randomized to ADT plus orteronel had a median overall survival (OS) of 81 months compared with 70.2 months with ADT plus […]
Another Link Between Prostate Cancer Hormone Tx and Impaired Cognition
Hormonal therapy for advanced prostate cancer, particularly enzalutamide (Xtandi), had a significant association with cognitive impairment, an analysis of a large drug-safety database showed. Traditional hormonal therapy increased the odds of cognitive impairment by 47% versus men who did not receive the therapy. The odds more than doubled among men who received novel androgen receptor […]
Testicular Mass Serendipitously Found 12 Years After Prostate Cancer Dx
A 79-year-old man with a 12-year history of clinically localized prostate cancer presented to a hospital with a urethral stricture. He had developed radiation cystitis and low-grade non-invasive urothelial carcinoma of the bladder some time after he received proton therapy following his prostate cancer diagnosis. In the process of prepping the patient for cystoscopic dilation […]
For Men on ADT, Checking Bone Density May Thwart Fractures
Bone density testing in older prostate cancer patients on androgen deprivation therapy (ADT) was significantly associated with a decreased risk for major osteoporotic fractures, but remains little used, a prospective population-based study found. In the cohort of nearly 55,000 men treated with ADT from 2005 to 2015, those who received dual x-ray absorptiometry (DXA) screening […]
FDA Approves First Targeted Radioligand Therapy for Metastatic Prostate Cancer
On Wednesday, the FDA approved the first targeted therapeutic radioligand for progressive, metastatic castration-resistant prostate cancer (mCRPC) with prostate-specific membrane antigen (PSMA) expression. Consisting of a targeting compound and a therapeutic radioisotope, lutetium Lu 177 vipivotide tetraxetan (Pluvicto) hones in on PSMA-expressing mCRPC, as identified by a companion diagnostic test (gallium Ga 68 Gozetotide injection, […]